Pharma shares gain; Sun Pharma hits seven-month high
Wockhadrt, Biocon, Ipca Laboratories, Glenmark Pharmaceuticals, Lupin and Cadila Healthcare were up more than 2% on the National Stock Exchange.
 "Pharma shares gain; Sun Pharma hits seven-month high")
premium
Shares of pharmaceutical companies were in focus with most of the frontline stocks trading higher in the range of 2% to 8% on BSE.
Sun Pharmaceutical Industries, Wockhadrt, Biocon, Ipca Laboratories, Glenmark Pharmaceuticals, Lupin and Cadila Healthcare were up more than 2% on the National Stock Exchange (NSE).
At 09:50 AM; Nifty Pharma index, the largest gainer among sectoral indices, was up 2.3% at 9,927, as compared to 0.53% rise in the Nifty 50 index. The pharma index hits two-month high of 9,939 in intra-day trade so far.
Among the individual stocks, Sun Pharma was up 4% at Rs 605, hits seven month high on the NSE. The stock was trading at its highest level since May 25, 2017 after media reports suggested that the US Food and Drug Administration (USFDA) is expected to begin inspection of Sun Pharma manufacturing facility at Halol in the second week of February.
In past two weeks, the stock of Sun Pharma has outperformed the market by gaining 12% after the company on December 27 said that the USFDA accepted its application for a novel medicine to treat dry-eye disease.
“Sun Pharma has outperformed vs. large cap peers in the last 6 months despite the large earnings disappointment in FY18 so far. We like Sun Pharma’s specialty strategy for long-term growth. However, at current valuations of the US business, the stock is pricing in the recovery in earnings trajectory from potential clearance in Halol’s status and successful execution of its Specialty pipeline over the next 5 years,” analyst at JP Morgan said in pharma sector update.
The brokerage firm believes there is risk to Sun Pharma’s consensus earnings given FY19 margin assumes strong launch pipeline post Halol, lower erosion in Taro and limited investment in the specialty business. Further, there is also the risk from failure or delay in the specialty pipeline, which is not factored in the current premium valuations.
While the issues in the US generic industry are likely to persist into 2018, analyst believe FDA’s efforts towards faster approvals particularly limited-competition drugs should provide upside for pharmaceutical companies from 2HCY18.
Sun Pharmaceutical Industries, Wockhadrt, Biocon, Ipca Laboratories, Glenmark Pharmaceuticals, Lupin and Cadila Healthcare were up more than 2% on the National Stock Exchange (NSE).
At 09:50 AM; Nifty Pharma index, the largest gainer among sectoral indices, was up 2.3% at 9,927, as compared to 0.53% rise in the Nifty 50 index. The pharma index hits two-month high of 9,939 in intra-day trade so far.
Among the individual stocks, Sun Pharma was up 4% at Rs 605, hits seven month high on the NSE. The stock was trading at its highest level since May 25, 2017 after media reports suggested that the US Food and Drug Administration (USFDA) is expected to begin inspection of Sun Pharma manufacturing facility at Halol in the second week of February.
In past two weeks, the stock of Sun Pharma has outperformed the market by gaining 12% after the company on December 27 said that the USFDA accepted its application for a novel medicine to treat dry-eye disease.
“Sun Pharma has outperformed vs. large cap peers in the last 6 months despite the large earnings disappointment in FY18 so far. We like Sun Pharma’s specialty strategy for long-term growth. However, at current valuations of the US business, the stock is pricing in the recovery in earnings trajectory from potential clearance in Halol’s status and successful execution of its Specialty pipeline over the next 5 years,” analyst at JP Morgan said in pharma sector update.
The brokerage firm believes there is risk to Sun Pharma’s consensus earnings given FY19 margin assumes strong launch pipeline post Halol, lower erosion in Taro and limited investment in the specialty business. Further, there is also the risk from failure or delay in the specialty pipeline, which is not factored in the current premium valuations.
While the issues in the US generic industry are likely to persist into 2018, analyst believe FDA’s efforts towards faster approvals particularly limited-competition drugs should provide upside for pharmaceutical companies from 2HCY18.
| COMPANY | LATEST | PREV CLOSE | GAIN(%) |
| WOCKHARDT | 1010.00 | 936.95 | 7.8 |
| SUN PHARMA.INDS. | 602.35 | 578.75 | 4.1 |
| SYNGENE INTL. | 594.95 | 572.15 | 4.0 |
| MARKSANS PHARMA | 43.30 | 41.85 | 3.5 |
| BIOCON | 558.10 | 541.20 | 3.1 |
| LUPIN | 923.45 | 899.15 | 2.7 |
| CADILA HEALTH. | 452.05 | 440.45 | 2.6 |
| GLENMARK PHARMA. | 607.00 | 592.45 | 2.5 |
| IPCA LABS. | 596.05 | 582.85 | 2.3 |
| GLAXOSMI. PHARMA | 2533.00 | 2478.95 | 2.2 |
| DIVI'S LAB. | 1127.00 | 1105.15 | 2.0 |
| NATCO PHARMA | 1018.55 | 998.90 | 2.0 |
| STRIDES SHASUN | 830.35 | 817.85 | 1.5 |
| UNICHEM LABS. | 356.50 | 351.55 | 1.4 |
| J B CHEM & PHARM | 333.00 | 328.40 | 1.4 |
| AUROBINDO PHARMA | 680.35 | 671.10 | 1.4 |
| SHILPA MEDICARE | 615.00 | 607.15 | 1.3 |
| DR REDDY'S LABS | 2499.00 | 2467.35 | 1.3 |
| SUVEN LIFE SCIE. | 217.80 | 215.10 | 1.3 |
| CIPLA | 620.40 | 613.00 | 1.2 |
One subscription. Two world-class reads.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%